Jitka Malčíková

2017

• KOTASKOVA, J; PAVLOVA, S; PLEVOVA, K; MALCIKOVA, J; STEHLIKOVA, O; POPPOVA, L; KOCKOVA, H; DOUBEK, M; BRYJA, V; POSPISILOVA, S, 2017:TREATMENT WITH BCR INHIBITORS INCREASES ROR1 EXPRESSION IN CLL CELLS. HAEMATOLOGICA 102 , p. 414 - 414.
• PLEVOVA, K; MALCIKOVA, J; PAVLOVA, S; KOTASKOVA, J; POPPOVA, L; SMARDOVA, J; DIVISKOVA, E; DURECHOVA, K; OLTOVA, A; BRYCHTOVA, Y; PANOVSKA, A; DOUBEK, M; POSPISILOVA, S, 2017:BIALLELIC TP53 GENE MUTATIONS DUE TO COPY-NEUTRAL LOSS OF HETEROZYGOSITY AND MONOALLELIC MUTATIONS IN ABSENCE OF 17P DELETION OCCUR IN CLL WITH COMPARABLE FREQUENCY. HAEMATOLOGICA 102 , p. 65 - 66.

2016

• JASKOVA, Z; MALCIKOVA, J; SMARDOVA, J; BRYCHTOVA, Y; DOUBEK, M; TRBUSEK, M, 2016:PRO-APOPTOTIC EFFECTS OF PRIMA-1MET CORRELATE WITH NOXA GENE INDUCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS. HAEMATOLOGICA 101 , p. 226 - 226.
• KUBESOVA, B; PAVLOVA, S; MALCIKOVA, J; KABATHOVA, J; RADOVA, L; TOM, N; TICHY, B; PLEVOVA, K; KANTOROVA, B; FIEDOROVA, K; KISSOVA, J; GISSLINGER, B; GISSLINGER, H; MAYER, J; KRALOVICS, R; POSPISILOVA, S; DOUBEK, M, 2016:Low-Burden TP53 Mutations Occur in Chronic Phase of Myeloproliferative Neoplasms Regardless of Hydroxyurea Administration, Disease Type, and JAK2 Status. BLOOD 128 (22)
• POSPISILOVA, S; SUTTON, LA; MALCIKOVA, J; TAUSCH, E; ROSSI, D; MONTSERRAT, E; MORENO, C; STAMATOPOULOS, K; GAIDANO, G; ROSENQUIST, R; GHIA, P, 2016:Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?. HAEMATOLOGICA 101 (3), p. 263 - 265.
• SUTTON, LA; YOUNG, E; BALIAKAS, P; HADZIDIMITRIOU, A; MOYSIADIS, T; PLEVOVA, K; ROSSI, D; KMINKOVA, J; STALIKA, E; PEDERSEN, LB; MALCIKOVA, J; AGATHANGELIDIS, A; DAVIS, Z; MANSOURI, L; SCARFO, L; BOUDJOGHRA, M; NAVARRO, A; MUGGEN, AF; YAN, XJ; NGUYEN-KHAC, F; LARRAYOZ, M; PANAGIOTIDIS, P; CHIORAZZI, N; NIEMANN, CU; BELESSI, C; CAMPO, E; STREFFORD, JC; LANGERAK, AW; OSCIER, D; GAIDANO, G; POSPISILOVA, S; DAVI, F; GHIA, P; STAMATOPOULOS, K; ROSENQUIST, R, 2016:Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. HAEMATOLOGICA 101 (8), p. 959 - 967.
• ZAPRAZNA, K; MALCIKOVA, J; TOM, N; RADOVA, L; TRBUSEK, M; ATCHISON, M; POSPISILOVA, S, 2016:ACTIVATION INDUCED DEAMINASE SPLICE VARIANTS EXPRESSED IN B CELL LEUKEMIA AND LYMPHOMA DO NOT RETAIN THEIR CATALYTIC ACTIVITY. HAEMATOLOGICA 101 , p. 429 - 430.

2015

• JASKOVA, Z; MALCIKOVA, J; SMARDOVA, J; BRYCHTOVA, Y; MAYER, J; TRBUSEK, M, 2015:ELIMINATION OF MUTATED P53 PROTEIN AND INDUCTION OF P53 DOWNSTREAM GENES IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS USING PRIMA-1MET. HAEMATOLOGICA 100 , p. 414 - 414.
• KANTOROVA, B; MALCIKOVA, J; BRAZDILOVA, K; BORSKY, M; PLEVOVA, K; SMARDOVA, J; TRBUSEK, M; BRYCHTOVA, Y; DOUBEK, M; MAYER, J; POSPISILOVA, S, 2015:Single Cell Analysis Proves the Coexistence of NOTCH1 and TP53 Mutations within the Same Cancer Cells in Patients with Chronic Lymphocytic Leukemia. BLOOD 126 (23)
• KOTASKOVA, J; MALCIKOVA, J; DIVISKOVA, E; PAVLOVA, S; MEJSTRIKOVA, S; VRANOVA, V; PLEVOVA, K; PLESINGEROVA, H; DOUBEK, M; MAYER, J; POSPISILOVA, S, 2015:13Q DELETION IS PREDOMINANT CYTOGENETIC ABERRATION NEWLY AQUIRED DURING CHRONIC LYMPHOCYTIC LEUKEMIA COURSE IRRESPECTIVE OF DISEASE ACTIVITY AND TREATMENT STATUS. HAEMATOLOGICA 100 , p. 417 - 418.
• MALCIKOVA, J; STANO-KOZUBIK, K; TICHY, B; KANTOROVA, B; PAVLOVA, S; TOM, N; RADOVA, L; SMARDOVA, J; PARDY, F; DOUBEK, M; BRYCHTOVA, Y; MRAZ, M; PLEVOVA, K; DIVISKOVA, E; OLTOVA, A; MAYER, J; POSPISILOVA, S; TRBUSEK, M, 2015:Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. LEUKEMIA 29 (4), p. 877 - 885.
• SUTTON, LA; LJUNGSTROM, V; MANSOURI, L; YOUNG, E; CORTESE, D; NAVRKALOVA, V; MALCIKOVA, J; MUGGEN, AF; TRBUSEK, M; PANAGIOTIDIS, P; DAVI, F; BELESSI, C; LANGERAK, AW; GHIA, P; POSPISILOVA, S; STAMATOPOULOS, K; ROSENQUIST, R, 2015:Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting. HAEMATOLOGICA 100 (3), p. 370 - 376.
• TE RAA, GD; DERKS, IAM; NAVRKALOVA, V; SKOWRONSKA, A; MOERLAND, PD; VAN LAAR, J; OLDREIVE, C; MONSUUR, H; TRBUSEK, M; MALCIKOVA, J; LODEN, M; GEISLER, CH; HULLEIN, J; JETHWA, A; ZENZ, T; POSPISILOVA, S; STANKOVIC, T; VAN OERS, MHJ; KATER, AP; ELDERING, E, 2015:The impact of SF3B1 mutations in CLL on the DNA-damage response. LEUKEMIA 29 (5), p. 1133 - 1142.
• TOM, N; MALCIKOVA, J; RADOVA, L; KANTOROVA, B; PARDY, F; PAVLOVA, S; PAL, K; MRAZ, M; TICHY, B; DOUBEK, M; BRYCHTOVA, Y; PLEVOVA, K; MAYER, J; TRBUSEK, M; POSPISILOVA, S, 2015:MUTATIONS IN THE TP53 GENE SHOW FEATURES OF SOMATIC HYPERMUTATION PROCESS WITH PROMINENT DIFFERENCE BETWEEN IGHV MUTATED AND UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA 100 , p. 224 - 225.
• ZEMANOVA, J; PARUCH, K; KREJCI, L; SOUCEK, K; HYLSE, O; BOUDNY, M; BORSKY, M; OSICKOVA, J; KHIRSARIYA, P; SEBEJOVA, L; NAVRKALOVA, V; MALCIKOVA, J; DIVISKOVA, E; BRYCHTOVA, Y; MAYER, J; TRBUSEK, M, 2015:CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE HIGHLY SUSCEPTIBLE TO DIRECT INHIBITION OF CHECKPOINT KINASE 1. HAEMATOLOGICA 100 , p. 417 - 417.